Estrella ImmunoPharma, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 16, 2026, reporting a net loss of $7,382,080 and cash and cash equivalents of $92,458 at quarter end.

Key Highlights

  • Net loss of $7,382,080 for the three months ended September 30, 2026, compared to a net loss of $4,801,149 for the same period in 2025, according to the filing.
  • Cash and cash equivalents of $92,458 as of September 30, 2026, down from $1,384,302 as of December 31, 2025.
  • Total stockholders' deficit of $(13,971,704) as of September 30, 2026, compared to $(10,366,058) as of December 31, 2025.
  • Accumulated deficit of $48,971,298 as of September 30, 2026, up from $36,990,815 as of December 31, 2025.
  • Research and development expenses of $6,900,396 for the three months ended September 30, 2026, compared to $4,152,642 for the three months ended September 30, 2025.
  • 43,970,085 shares of common stock outstanding as of November 11, 2026, per the filing cover page.

Estrella ImmunoPharma's Financial Position for the Quarter Ended September 30, 2026

Estrella ImmunoPharma, Inc. (NASDAQ:ESLA), a Delaware-incorporated biopharmaceutical company headquartered in Emeryville, California, reported a net loss of $7,382,080 for the three months ended September 30, 2026, according to its quarterly filing. This compares to a net loss of $4,801,149 for the corresponding quarter in 2025. For the nine months ended September 30, 2026, the company reported a net loss of $11,980,483, versus $12,450,338 for the nine months ended September 30, 2025.

The company's total operating expenses for the three months ended September 30, 2026 were $7,496,223, consisting of research and development expenses of $6,900,396 and general and administrative expenses of $595,827. The filing noted that both research and development and general and administrative line items include related party expenses. Net loss per share, basic and diluted, was $(0.17) for the three months ended September 30, 2026, based on a weighted average of 43,589,651 common shares outstanding.

As of September 30, 2026, the company reported total assets of $1,671,026, against total liabilities of $15,642,730, resulting in a total stockholders' deficit of $(13,971,704). Current liabilities included an accrued liability classified as related party of $15,323,077. Cash and cash equivalents stood at $92,458 at September 30, 2026, a sharp decline from $1,384,302 at December 31, 2025. The filing also reflects 44,485,366 shares issued and 43,970,085 shares outstanding as of September 30, 2026, with 515,281 shares held as treasury stock.

What Was Disclosed

The filing discloses Estrella ImmunoPharma's unaudited condensed consolidated financial statements for the quarter and nine months ended September 30, 2026, including a net loss of $7,382,080 for the quarter, cash of $92,458, and a total stockholders' deficit of $(13,971,704).